Trial Profile
Ribavirin/Pegasys [peginterferon alfa-2a] treatment of recurrent hepatitis C after liver transplant.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Jul 2007 New trial record.